According to some exemplary embodiments, a system is provided comprising a hardware processor executing instructions stored on a non-transitory media, the instructions for a method for providing real-time assessment of a potential risk of an infectious disease without face-to-face interaction between a human user and a human healthcare professional, the method including receiving a predetermined acceptable range for an aspect of a human user's physiological measurement data, receiving a predetermined acceptable answer for a survey response question, securely receiving an aspect of the human user's physiological measurement data, determining if the aspect of the human user's physiological measurement data is within the predetermined acceptable range, if the aspect of the human user's physiological measurement data is within the predetermined acceptable range, transmitting to the human user a survey comprising a question, if the aspect of the human user's physiological measurement data is not within the predetermined acceptable range, transmitting an active alert and not providing the human user with the survey comprising a question, and if the human user fails to transmit an acceptable answer to the survey comprising the question, transmitting an active alert.
In further exemplary embodiments, if the aspect of the human user's physiological measurement data is not within the predetermined acceptable range, infectious disease exposure risk survey questions may be transmitted to the human user. Additionally, an active alert may be transmitted to a graphical user interface. A login may be received from the human user and an active alert may be sent if the login from the human user is not received.
Some exemplary systems may be embedded within a kiosk. The survey may be presented with a networked interactive animated conversational graphical user interface configured to provide, in real-time, a consultative recommendation. The human user's physiological measurement data may include temperature, oxygen saturation, weight, blood glucose level, and blood pressure data and may be received from a networked or non-networked peripheral device. The peripheral device may be any of a thermometer, pulse oximeter, blood pressure monitor, spirometer or a scale and may have a hardware processor.
Certain exemplary embodiments may determine and display a potential risk of an infectious disease, including displaying, in real-time, a warning of a potential risk of an infectious disease based on multivariate analyses through supervised and unsupervised machine learning approaches. The displaying may also include securely transmitting the human user's physiological measurement data and survey answer using HIPAA-compliant AES-256 bit encryption. A cloud-based normative data storage having a normative data threshold, a risk ratio, and a recommendation may be accessed and the human user's physiological measurement data may be compared to the normative data threshold and the risk ratio. Based on the comparison, a warning or an approval to enter a facility may be determined and the warning or the approval to enter a facility may be transmitted through the AES-256 bit encryption.
A mobile device, according to various exemplary embodiments, may have an application for the displaying and transmitting of information from and to the system. The information may be used to determine whether access will be granted to an event or venue, and the information may be displayed as a QR code. Additionally, an electronically transferable access pass to an event or venue may be included and the electronically transferable access pass to the event or venue may only be transferable to another device with access granted to the event or venue.
The accompanying drawings, where like reference numerals refer to identical or functionally similar elements throughout the separate views, together with the detailed description below, are incorporated in and form part of the specification, and serve to further illustrate embodiments of concepts that include the claimed disclosure, and explain various principles and advantages of those embodiments.
The methods and systems disclosed herein have been represented where appropriate by conventional symbols in the drawings, showing only those specific details that are pertinent to understanding the embodiments of the present disclosure so as not to obscure the disclosure with details that will be readily apparent to those of ordinary skill in the art having the benefit of the description herein.
Part I. AddisonPass™ Platform Overview
Introduction
The Electronic Caregiver (ECG) AddisonPass™ Access Management Program (AddisonPass) is a technology platform allowing the assessment and monitoring of individuals prior to their entry into a specified facility, venue, academic institution or business. Integration of AddisonPass™ allows individuals to efficiently enter these areas by analyzing the answers to questionnaire(s) from health organizations (e.g., CDC, WHO) and verified biometric data through a secure, password protected web and/or mobile application providing a pass/fail result for entry. Organizations (e.g., schools, businesses, Houses of Worship) are thus better able to identify and proactively manage entry without having to apply separate resources, manually track symptomology, or manage access at point-of-entry at significant additional costs and logistical complexity. The AddisonPass™ platform specifically allows individuals to proactively and confidentially track symptomology and make better informed choices regarding health status and whether or not to proceed to a venue. Moreover, the questions around symptomology can be adjusted in real-time based on health organization recommendations as well as responses provided to prior questions, thus creating a dynamic assessment of health and wellness of the individual. AddisonPass™ also supports organizations in maintaining individual and customer safety, as well as reducing the amount of time employees lose to illness by reducing the likelihood of spread. Importantly, this system can be integrated into schools, universities, and additional ‘superspreader’ environments where many people gather. With this data, organizations can confidently inform employees and customers whether to work, study, and shop remotely, or to proceed to the venue for an in-person experience. Adoption of the AddisonPass™ platform on an individual, business and community level allows for a single, consistent and reliable system to manage entry across multiple organizations without inconsistency in collection and reporting methodology, and at significantly lower cost and risk as compared with other current models. Additionally, capture of this data can be combined with publicly available test results to improve the science behind understanding prevalence of symptomology, length of symptomology and other infectious disease information for the betterment of public health efforts around any pathogen. Importantly, this model can improve efficiency in operations while minimizing manual efforts and the number of staff needed to manage the reentry process as safely as possible.
AES—Advanced Encryption Standard
AWS—Amazon Web Services
ECG—Electronic Caregiver, Inc
GCP—Google Cloud Platform
GUI—Graphical User Interface
HIPAA—Health Insurance Portability and Accountability
IUM—Individual Use Model
Part 2. AddisonPass™ Product Types
Introduction
The typical end-user will enroll in the ECG AddisonPass™ platform. This will allow the individual to perform screening via biometric data and questionnaire survey inputs on a web-connected device to create a pass/fail result specific to the infectious disease being monitored. A pass result indicates that the individual may be allowed into the venue based on their questionnaire and biometric data, while a fail result indicates that they should not be allowed entry. The pass/fail result can be stored on their phone as a unique scannable code to be presented as a verified, digital, trusted certificate of safety at point-of-entry to a venue. Though the specific answers to screening questions will be available to the end user, the only information accessible to organizations (captured via mobile device, tablet, or other internet-connected or Bluetooth® device), besides demographics data associated with the individual, will be the pass/fail result. End-user protected health information will not be available to organizations. In some embodiments, a credentialed organization member may log into a dashboard to view the data. Participating organizations would then use either a kiosk model or a manual checking process to scan this code and track approved entry versus unapproved entry. This is similar in principle to a TSA agent checking for “TSA Pre-Check” on a passenger's ticket. The process for scanning mobile phones for tickets is widely used now at airports, concert halls, and sporting arenas, and therefore this physical infrastructure could be leveraged at nominal expense for this additional screening. This is expected to be significantly more efficient and comprehensive than a superficial manual screening at point-of-entry for attendees. The ECG platform will be supported on multiple platforms and through available scanning devices, as this decision is the purview of the organization. By providing various options related to platform deployment, ECG can enhance market penetration opportunities and provide customer-centric, iterative versions of the AddisonPass™. The current delivery modalities available for the ECG AddisonPass™ include an individual use model and a kiosk deployment model, as represented in
2.1 Individual Use Model
The individual use model for deployment provides disparate organizations, through a web application that can monitor activity on an individual level, with actionable data describing infectious disease exposure risks. Based on the ability for an individual to report symptomology and biometric data, the pass/fail score can be read at entry points for a given individual. The pass/fail result is determined using both machine learning and prescribed acceptable ranges of responses to determine an individual's relative risk of infection. After an organization completes the onboarding process, ECG is responsible for provisioning their individual-specific login credentials and providing those login credentials to the organization.
2.2 Organizational Use Model
Organizations, who may incorporate this system as part of a program for a wide variety of purposes for its customers (e.g., rewards or incentive program, financial insurance program, safety initiative), may also provide this program on behalf of their customers. For instance, users could be identified by the organization and ECG would provide log in credentials to the identified users. In this case, the organization is responsible for payment of fees (whole or partial) depending on their reward and incentive rules. Regardless of the exact usage scenario, the delivered results to the end user would be scanned at a kiosk or through other scanning methodology at point of entry at participating organizations.
Data collected via the AddisonPass™ platform may also be routed to an interactive GUI and notification system for review by an individual (or a team of individuals) designated to make decisions concerning entry to a facility. Additionally, machine learning algorithms imbedded within the platform, as depicted in
As depicted in
2.3 Insurance Product in Individual Risk Protection Model
The AddisonPass™ Access Control Management platform can also be used in conjunction with a form of individual protection at the event, business or venue level (e.g., concerts, sporting events). In one case, the individual participates in a ‘pool,’ such that if they are unable to participate or attend an event, they can sell or trade their ‘ticket’ with someone in the pool who is not potentially ill. This creates incentive for any individual user to answer honestly as it minimizes risk of potential financial damages. Support to venues and events is provided by minimizing risks of potentially ill attendees going to events, while maximizing chances of filling venues to capacity.
The AddisonPass™ Access Control Management platform could also be used as part of an insurance program that allows sharing of risk across populations. Similar to other types of trip or travel interruption insurance, or insurance made available for ticket purchases through a broker such as TicketMaster, this model supports honest self-reporting of symptomology by individuals and minimizes financial risk. Importantly because this model provides some protection from financial risk to the individuals as noted above, it minimizes the risk of spread of infection within the community while allowing maximum access to services and products that are a vital part of the economy. This form of rewarding desired behavior and minimizing negative consequences for self-reporting is important not only for the economy, but also for helping to create a culture of acceptance and fostering a positive vision of a post-pandemic society.
Part 3. AddisonPass™ Work/Data Flows
Introduction
Data flows are designed to provide real-time, actionable data to organizations/clinicians. This platform effectively functions to reduce the risk of disease spread, improve workplace safety and provide high-confidence access to the safety of venues.
3.1 Health Insurance Portability and Data Privacy (e.g., HIPAA and GDRP) Compliance
Individual privacy and data security are two factors that have been integrated into the AddisonPass™ platform from product inception through product delivery. All data collection and transmission occurring via the ECG AddisonPass™ platform are compliant with HIPAA requirements. All data are AES-256 bit encrypted upon ingestion into the end-user hardware and remain encrypted through transit and deposit into the ECG cloud-hybrid infrastructure. All data remain AES-256 bit encrypted at rest within the system as well.
3.2 Organizational Workflow
The workflow presented herein is deployable across a wide spectrum of infectious diseases. In general, upon registration of an organization (i.e.—school, employer, business, House of Worship, etc.) for AddisonPass™ use, ECG will immediately work to establish an account for the organization. Once ECG has registered the organization, ECG will provide them with all affiliated users login information. Upon receipt of login information, the organization provides credentials to their registered users.
Once a registered user has received their login credentials, the user will log into the platform and follow the provided prompts. This workflow is depicted in
Following the completion of the onboarding, training and delivery processes associated with AddisonPass™, the platform is now available for implementation and use. To use the platform, an end user (e.g., employee, customer) will log into the AddisonPass™ portal and complete the infectious disease risk assessment as depicted in
3.3 AddisonPass™ Data Flow
Part 4. AddisonPass™ User Interfaces
Introduction
Collecting data describing biometric data and survey responses as they relate to risk of infectious disease spread is one functional aspect of the AddisonPass™. The second functional aspect of the platform is to provide an interface through which the platform delivers these data to a remotely accessible portal for review by the contracting organization. This portal provides decision makers within the organization with access to user survey response and biometric data without in-person, physical contact—which is critical during times of infectious disease spread and risk. This protocol design allows organizations to safely screen users and proactively address risk of exposure to infectious disease based on their defined levels of risk tolerance. By providing a method for front-end user experience through the AddisonPass™ web application and delivering a backend user experience through the AddisonPass™ Dashboard, ECG can collect and deliver biometric and survey response data via user friendly interfaces in a HIPAA compliant manner.
Through enhanced engagement, employers/organizations are provided with the capacity for making real-time, case-by-case determinations of whether a front-end user should enter a facility. This allows employers and organizations to maintain their independence and autonomy in safely managing access to their facilities. In doing so, employers and organizations can limit the unintended spread of infectious disease by asymptomatic carriers. Successfully adopting the ECG AddisonPass™ platform enables organizations to re-open to employees and customers in an informed, data-driven manner. Additionally, by demonstrating evidence of data-driven decisions, employers/organizations can better provide employees/customers with higher levels of confidence and peace-of-mind when entering new environments. Together, this will significantly reduce unintended disease spread while simultaneously enabling a reopening of economic activity.
4.1 AddisonPass™ Front End User Experience
The ECG AddisonPass™ provides an interactive front-end user experience. When provided with login credentials by their employer/organization, the front-end user is also provided with a link to the application portal. By selecting the link, the front-end user is directed to the appropriate web portal site. Upon reaching the designated site, the front-end user is presented with the login screen displayed in
Once logged in, the front-end user is directed to a page requesting a selection for biometric data collection modality as displayed in
Following reingestion of biometric data, the front-end user is then provided the survey displayed in
AddisonPass™ results.
Once all data collection has been completed, the AddisonPass™ front-end user is then presented with the screen displayed in
Back-End User Experience
Following front-end user completion of the AddisonPass™ processes, all data are routed to a data portal which provides an opportunity for back-end users (typically organization designated) to review the data. The AddisonPass™ data portal is a proprietary GUI providing organizations/employers with the capacity for real time delivery of user data, alerts based on system intelligence and the capacity to actively respond to data-centric alerts to mitigate possible exposure to infectious disease. For dashboard use, credentialed organization members log into the data portal with provided credentials to reach the landing page displayed in
The corresponding structures, materials, acts, and equivalents of all means or step plus function elements in the claims below are intended to include any structure, material, or act for performing the function in combination with other claimed elements as specifically claimed. The description of the present disclosure has been presented for purposes of illustration and description, but is not intended to be exhaustive or limited to the present disclosure in the form disclosed. Many modifications and variations will be apparent to those of ordinary skill in the art without departing from the scope and spirit of the present disclosure. Exemplary embodiments were chosen and described in order to best explain the principles of the present disclosure and its practical application, and to enable others of ordinary skill in the art to understand the present disclosure for various embodiments with various modifications as are suited to the particular use contemplated.
While this technology is susceptible of embodiment in many different forms, there is shown in the drawings and will herein be described in detail several specific embodiments with the understanding that the present disclosure is to be considered as an exemplification of the principles of the technology and is not intended to limit the technology to the embodiments illustrated.
The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the technology. As used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprises” and/or “comprising,” when used in this specification, specify the presence of stated features, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and/or groups thereof.
It will be understood that like or analogous elements and/or components, referred to herein, may be identified throughout the drawings with like reference characters. It will be further understood that several of the figures are merely schematic representations of the present disclosure. As such, some of the components may have been distorted from their actual scale for pictorial clarity.
The flowchart and block diagrams in the Figures illustrate the architecture, functionality, and operation of possible implementations of systems, methods and computer program products according to various embodiments of the present disclosure. In this regard, each block in the flowchart or block diagrams may represent a module, segment, or portion of code, which comprises one or more executable instructions for implementing the specified logical function(s). It should also be noted that, in some alternative implementations, the functions noted in the block may occur out of the order noted in the figures. For example, two blocks shown in succession may, in fact, be executed substantially concurrently, or the blocks may sometimes be executed in the reverse order, depending upon the functionality involved. It will also be noted that each block of the block diagrams and/or flowchart illustration, and combinations of blocks in the block diagrams and/or flowchart illustration, can be implemented by special purpose hardware-based systems that perform the specified functions or acts, or combinations of special purpose hardware and computer instructions.
In the following description, for purposes of explanation and not limitation, specific details are set forth, such as particular embodiments, procedures, techniques, etc. in order to provide a thorough understanding of the present invention. However, it will be apparent to one skilled in the art that the present invention may be practiced in other embodiments that depart from these specific details.
Reference throughout this specification to “one embodiment” or “an embodiment” means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, the appearances of the phrases “in one embodiment” or “in an embodiment” or “according to one embodiment” (or other phrases having similar import) at various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments. Furthermore, depending on the context of discussion herein, a singular term may include its plural forms and a plural term may include its singular form. Similarly, a hyphenated term (e.g., “on-demand”) may be occasionally interchangeably used with its non-hyphenated version (e.g., “on demand”), a capitalized entry (e.g., “Software”) may be interchangeably used with its non-capitalized version (e.g., “software”), a plural term may be indicated with or without an apostrophe (e.g., PE's or PEs), and an italicized term (e.g., “N+1”) may be interchangeably used with its non-italicized version (e.g., “N+1”). Such occasional interchangeable uses shall not be considered inconsistent with each other.
Also, some embodiments may be described in terms of “means for” performing a task or set of tasks. It will be understood that a “means for” may be expressed herein in terms of a structure, such as a processor, a memory, an I/O device such as a camera, or combinations thereof. Alternatively, the “means for” may include an algorithm that is descriptive of a function or method step, while in yet other embodiments the “means for” is expressed in terms of a mathematical formula, prose, or as a flow chart or signal diagram.
The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprises” and/or “comprising,” when used in this specification, specify the presence of stated features, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and/or groups thereof.
It is noted at the outset that the terms “coupled,” “connected”, “connecting,” “electrically connected,” etc., are used interchangeably herein to generally refer to the condition of being electrically/electronically connected. Similarly, a first entity is considered to be in “communication” with a second entity (or entities) when the first entity electrically sends and/or receives (whether through wireline or wireless means) information signals (whether containing data information or non-data/control information) to the second entity regardless of the type (analog or digital) of those signals. It is further noted that various figures (including component diagrams) shown and discussed herein are for illustrative purpose only, and are not drawn to scale.
While specific embodiments of, and examples for, the system are described above for illustrative purposes, various equivalent modifications are possible within the scope of the system, as those skilled in the relevant art will recognize. For example, while processes or steps are presented in a given order, alternative embodiments may perform routines having steps in a different order, and some processes or steps may be deleted, moved, added, subdivided, combined, and/or modified to provide alternative or sub-combinations. Each of these processes or steps may be implemented in a variety of different ways. Also, while processes or steps are at times shown as being performed in series, these processes or steps may instead be performed in parallel, or may be performed at different times.
While various embodiments have been described above, it should be understood that they have been presented by way of example only, and not limitation. The descriptions are not intended to limit the scope of the invention to the particular forms set forth herein. To the contrary, the present descriptions are intended to cover such alternatives, modifications, and equivalents as may be included within the spirit and scope of the invention as defined by the appended claims and otherwise appreciated by one of ordinary skill in the art. Thus, the breadth and scope of a preferred embodiment should not be limited by any of the above-described exemplary embodiments.
The present application claims the priority benefit of U.S. Provisional Patent Application Ser. No. 63/055,236 filed on Jul. 22, 2020 titled “Systems and Methods for Mitigating the Spread of Infectious Diseases,” and the present application claims the priority benefit of U.S. Provisional Patent Application Ser. No. 63/067,757 filed on Aug. 19, 2020 titled “Systems and Methods for Reopening Venues and Businesses Through Mitigation of the Spread of Infectious Diseases,” which are incorporated by reference in their entireties.
Number | Name | Date | Kind |
---|---|---|---|
5211642 | Clendenning | May 1993 | A |
5475953 | Greenfield | Dec 1995 | A |
6665647 | Haudenschild | Dec 2003 | B1 |
7233872 | Shibasaki et al. | Jun 2007 | B2 |
7445086 | Sizemore | Nov 2008 | B1 |
7612681 | Azzaro et al. | Nov 2009 | B2 |
7971141 | Quinn et al. | Jun 2011 | B1 |
8206325 | Najafi et al. | Jun 2012 | B1 |
8771206 | Gettelman et al. | Jul 2014 | B2 |
9317916 | Hanina et al. | Apr 2016 | B1 |
9591996 | Chang et al. | Mar 2017 | B2 |
9972187 | Srinivasan et al. | May 2018 | B1 |
10387963 | Leise et al. | Aug 2019 | B1 |
10628635 | Carpenter, II et al. | Apr 2020 | B1 |
10813572 | Dohrmann et al. | Oct 2020 | B2 |
11113943 | Wright et al. | Sep 2021 | B2 |
11213224 | Dohrmann et al. | Jan 2022 | B2 |
20020062342 | Sidles | May 2002 | A1 |
20020196944 | Davis et al. | Dec 2002 | A1 |
20040109470 | Derechin et al. | Jun 2004 | A1 |
20050035862 | Wildman et al. | Feb 2005 | A1 |
20050055942 | Maelzer et al. | Mar 2005 | A1 |
20070238936 | Becker | Oct 2007 | A1 |
20080010293 | Zpevak et al. | Jan 2008 | A1 |
20080186189 | Azzaro et al. | Aug 2008 | A1 |
20090094285 | Mackle et al. | Apr 2009 | A1 |
20100124737 | Panzer | May 2010 | A1 |
20110092779 | Chang | Apr 2011 | A1 |
20110126207 | Wipfel et al. | May 2011 | A1 |
20110145018 | Fotsch et al. | Jun 2011 | A1 |
20110232708 | Kemp | Sep 2011 | A1 |
20120025989 | Cuddihy et al. | Feb 2012 | A1 |
20120075464 | Derenne et al. | Mar 2012 | A1 |
20120120184 | Fornell et al. | May 2012 | A1 |
20120121849 | Nojima | May 2012 | A1 |
20120154582 | Johnson et al. | Jun 2012 | A1 |
20120165618 | Algoo et al. | Jun 2012 | A1 |
20120179067 | Wekell | Jul 2012 | A1 |
20120179916 | Staker et al. | Jul 2012 | A1 |
20120229634 | Laett et al. | Sep 2012 | A1 |
20120253233 | Greene et al. | Oct 2012 | A1 |
20130000228 | Ovaert | Jan 2013 | A1 |
20130127620 | Siebers et al. | May 2013 | A1 |
20130145449 | Busser et al. | Jun 2013 | A1 |
20130167025 | Patri et al. | Jun 2013 | A1 |
20130204545 | Solinsky | Aug 2013 | A1 |
20130212501 | Anderson et al. | Aug 2013 | A1 |
20130237395 | Hjelt et al. | Sep 2013 | A1 |
20130289449 | Stone et al. | Oct 2013 | A1 |
20130303860 | Bender et al. | Nov 2013 | A1 |
20140128691 | Olivier | May 2014 | A1 |
20140142963 | Hill | May 2014 | A1 |
20140148733 | Stone et al. | May 2014 | A1 |
20140171039 | Bjontegard | Jun 2014 | A1 |
20140171834 | DeGoede et al. | Jun 2014 | A1 |
20140232600 | Larose et al. | Aug 2014 | A1 |
20140243686 | Kimmel | Aug 2014 | A1 |
20140257852 | Walker et al. | Sep 2014 | A1 |
20140267582 | Beutter et al. | Sep 2014 | A1 |
20140278605 | Borucki et al. | Sep 2014 | A1 |
20140330172 | Jovanov et al. | Nov 2014 | A1 |
20140337048 | Brown et al. | Nov 2014 | A1 |
20140358828 | Phillipps et al. | Dec 2014 | A1 |
20140368601 | deCharms | Dec 2014 | A1 |
20150019250 | Goodman et al. | Jan 2015 | A1 |
20150109442 | Derenne et al. | Apr 2015 | A1 |
20150169835 | Hamdan et al. | Jun 2015 | A1 |
20150359467 | Tran | Dec 2015 | A1 |
20160026354 | McIntosh et al. | Jan 2016 | A1 |
20160117470 | Welsh et al. | Apr 2016 | A1 |
20160154977 | Jagadish et al. | Jun 2016 | A1 |
20160217264 | Sanford | Jul 2016 | A1 |
20160253890 | Rabinowitz et al. | Sep 2016 | A1 |
20160267327 | Franz et al. | Sep 2016 | A1 |
20160314255 | Cook et al. | Oct 2016 | A1 |
20170000387 | Forth et al. | Jan 2017 | A1 |
20170000422 | Moturu et al. | Jan 2017 | A1 |
20170024531 | Malaviya | Jan 2017 | A1 |
20170055917 | Stone et al. | Mar 2017 | A1 |
20170140631 | Pietrocola et al. | May 2017 | A1 |
20170147154 | Steiner et al. | May 2017 | A1 |
20170192950 | Gaither et al. | Jul 2017 | A1 |
20170193163 | Melle et al. | Jul 2017 | A1 |
20170197115 | Cook et al. | Jul 2017 | A1 |
20170213145 | Pathak et al. | Jul 2017 | A1 |
20170273601 | Wang et al. | Sep 2017 | A1 |
20170300652 | Strobridge | Oct 2017 | A1 |
20170337274 | Ly et al. | Nov 2017 | A1 |
20170344706 | Torres et al. | Nov 2017 | A1 |
20170344832 | Leung et al. | Nov 2017 | A1 |
20180075558 | Hill, Sr. et al. | Mar 2018 | A1 |
20180165938 | Honda et al. | Jun 2018 | A1 |
20180182472 | Preston et al. | Jun 2018 | A1 |
20180189756 | Purves et al. | Jul 2018 | A1 |
20180322405 | Fadell et al. | Nov 2018 | A1 |
20180360349 | Dohrmann et al. | Dec 2018 | A9 |
20180368780 | Bruno et al. | Dec 2018 | A1 |
20190029900 | Walton et al. | Jan 2019 | A1 |
20190042700 | Alotaibi | Feb 2019 | A1 |
20190057320 | Docherty et al. | Feb 2019 | A1 |
20190090786 | Kim et al. | Mar 2019 | A1 |
20190116212 | Spinella-Mamo | Apr 2019 | A1 |
20190130110 | Lee et al. | May 2019 | A1 |
20190164015 | Jones, Jr. et al. | May 2019 | A1 |
20190196888 | Anderson et al. | Jun 2019 | A1 |
20190220727 | Dohrmann et al. | Jul 2019 | A1 |
20190259475 | Dohrmann et al. | Aug 2019 | A1 |
20190282130 | Dohrmann et al. | Sep 2019 | A1 |
20190286942 | Abhiram et al. | Sep 2019 | A1 |
20190311792 | Dohrmann et al. | Oct 2019 | A1 |
20190318165 | Shah et al. | Oct 2019 | A1 |
20190385749 | Dohrmann et al. | Dec 2019 | A1 |
20200101969 | Natroshvili et al. | Apr 2020 | A1 |
20200251220 | Chasko | Aug 2020 | A1 |
20200357256 | Wright et al. | Nov 2020 | A1 |
20210007631 | Dohrmann et al. | Jan 2021 | A1 |
20210049238 | Vaughn | Feb 2021 | A1 |
20210273962 | Dohrmann et al. | Sep 2021 | A1 |
20210358202 | Tveito et al. | Nov 2021 | A1 |
20210375084 | Aubrey | Dec 2021 | A1 |
20210398410 | Wright et al. | Dec 2021 | A1 |
Number | Date | Country |
---|---|---|
104361321 | Feb 2015 | CN |
106056035 | Oct 2016 | CN |
107411515 | Dec 2017 | CN |
111801645 | Oct 2020 | CN |
111801939 | Oct 2020 | CN |
111867467 | Oct 2020 | CN |
3740856 | Nov 2020 | EP |
3756344 | Dec 2020 | EP |
3768164 | Jan 2021 | EP |
3773174 | Feb 2021 | EP |
3815108 | May 2021 | EP |
3920797 | Dec 2021 | EP |
202027033318 | Oct 2020 | IN |
202027035634 | Oct 2020 | IN |
2002304362 | Oct 2002 | JP |
2005228305 | Aug 2005 | JP |
2016525383 | Aug 2016 | JP |
1020160040078 | Apr 2016 | KR |
1020200105519 | Sep 2020 | KR |
1020200121832 | Oct 2020 | KR |
1020200130713 | Nov 2020 | KR |
WO2000005639 | Feb 2000 | WO |
WO2014043757 | Mar 2014 | WO |
WO2018032089 | Feb 2018 | WO |
WO2019143397 | Jul 2019 | WO |
WO2019164585 | Aug 2019 | WO |
WO2019182792 | Sep 2019 | WO |
WO2019199549 | Oct 2019 | WO |
WO2019245713 | Dec 2019 | WO |
WO2020163180 | Aug 2020 | WO |
WO2020227303 | Nov 2020 | WO |
Entry |
---|
“International Search Report” and “Written Opinion of the International Searching Authority,” Patent Cooperation Treaty Application No. PCT/US2018/057814, Jan. 11, 2019, 9 pages. |
“International Search Report” and “Written Opinion of the International Searching Authority,” Patent Cooperation Treaty Application No. PCT/US2018/068210, Apr. 12, 2019, 9 pages. |
“International Search Report” and “Written Opinion of the International Searching Authority,” Patent Cooperation Treaty Application No. PCT/US2019/021678, May 24, 2019, 12 pages. |
“International Search Report” and “Written Opinion of the International Searching Authority,” Patent Cooperation Treaty Application No. PCT/US2019/025652, Jul. 18, 2019, 11 pages. |
“International Search Report” and “Written Opinion of the International Searching Authority,” Patent Cooperation Treaty Application No. PCT/US2019/034206, Aug. 1, 2019, 11 pages. |
Rosen et al., “Slipping and Tripping: Fall Injuries in Adults Associated with Rugs and Carpets,” Journal of Injury & Violence Research, 5(1), (2013), pp. 61-69. |
Bajaj, Prateek, “Reinforcement Learning”, GeeksForGeeks.org [online], [retrieved on Mar. 4, 2020], Retrieved from the Internet :<URL:https://www.geeksforgeeks.org/what-is-reinforcement-learning/>, 7 pages. |
Kung-Hsiang, Huang (Steeve), “Introduction to Various RL Algorithms. Part I (Q-Learning, Sarsa, DQN, DDPG)”, Towards Data Science, [online], [retrieved on Mar. 4, 2020], Retrieved from the Internet:<URL:https://towardsdatascience.com/introduction-to-various-reinforcement-learning-algorithms-i-q-learning-sarsa-dqn-ddpg-72a5e0cb6287>, 5 pages. |
Bellemare et al., A Distributional Perspective on Reinforcement Learning:, Proceedings of the 34th International Conference on Machine Learning, Sydney, Australia, Jul. 21, 2017, 19 pages. |
Friston et al., “Reinforcement Learning or Active Inference?” Jul. 29, 2009, [online], [retrieved on Mar. 4, 2020], Retrieved from the Internet:<URL:https://doi.org/10.1371/journal.pone.0006421 PLoS ONE 4(7): e6421>, 13 pages. |
Zhang et al., “DQ Scheduler: Deep Reinforcement Learning Based Controller Synchronization in Distributed SDN” ICC 2019—2019 IEEE International Conference on Communications (ICC), Shanghai, China, doi: 10.1109/ICC.2019.8761183, pp. 1-7. |
“International Search Report” and “Written Opinion of the International Searching Authority,” Patent Cooperation Treaty Application No. PCT/US2020/031486, Aug. 3, 2020, 7 pages. |
“International Search Report” and “Written Opinion of the International Searching Authority,” Patent Cooperation Treaty Application No. PCT/US2020/016248, May 11, 2020, 7 pages. |
“Office Action”, Australia Patent Application No. 2019240484, Nov. 13, 2020, 4 pages. |
“Office Action”, Australia Patent Application No. 2018403182, Feb. 5, 2021, 5 pages. |
“Office Action”, Australia Patent Application No. 2018409860, Feb. 10, 2021, 4 pages. |
Leber, Jessica, “The Avatar Will See You Now”, MIT Technology Review, Sep. 17, 2013, 4 pages. |
“Office Action”, India Patent Application No. 202027035634, Jun. 30, 2021, 10 pages. |
“Office Action”, India Patent Application No. 202027033121, Jul. 29, 2021, 7 pages. |
“Office Action”, Canada Patent Application No. 3088396, Aug. 6, 2021, 7 pages. |
“Office Action”, China Patent Application No. 201880089608.2, Aug. 3, 2021, 8 pages. |
“Office Action”, Japan Patent Application No. 2020-543924, Jul. 27, 2021, 3 pages [6 pages with translation]. |
“Office Action”, Australia Patent Application No. 2019240484, Aug. 2, 2021, 3 pages. |
“Office Action”, Canada Patent Application No. 3089312, Aug. 19, 2021, 3 pages. |
“Extended European Search Report”, European Patent Application No. 18901139.8, Sep. 9, 2021, 6 pages. |
“Office Action”, Canada Patent Application No. 3091957, Sep. 14, 2021, 4 pages. |
“Office Action”, Japan Patent Application No. 2020-540382, Aug. 24, 2021, 7 pages [13 pages with translation]. |
“Extended European Search Report”, European Patent Application No. 18907032.9, Oct. 15, 2021, 12 pages. |
Marston et al., “The design of a purpose-built exergame for fall prediction and prevention for older people”, European Review of Aging and Physical Activity 12:13, <URL:https://eurapa.biomedcentral.com/track/pdf/10.1186/s11556-015-0157-4.pdf>, Dec. 8, 2015, 12 pages. |
Ejupi et al., “Kinect-Based Five-Times-Sit-to-Stand Test for Clinical and In-Home Assessment of Fall Risk in Older People”, Gerontology (vol. 62), (May 28, 2015), <URL:https://www.karger.com/Article/PDF/381804>, May 28, 2015, 7 pages. |
Festl et al., “iStoppFalls: A Tutorial Concept and prototype Contents”, <URL:https://hcisiegen.de/wp-uploads/2014/05/isCtutorialdoku.pdf>, Mar. 30, 2013, 36 pages. |
“Notice of Allowance”, Australia Patent Application No. 2019240484, Oct. 27, 2021, 4 pages. |
“Extended European Search Report”, European Patent Application No. 19772545.0, Nov. 16, 2021, 8 pages. |
“Office Action”, India Patent Application No. 202027033318, Nov. 18, 2021, 6 pages. |
“Office Action”, Australia Patent Application No. 2018409860, Nov. 30, 2021, 4 pages. |
“Office Action”, Australia Patent Application No. 2018403182, Dec. 1, 2021, 3 pages. |
“Office Action”, Korea Patent Application No. 10-2020-7028606, Oct. 29, 2021, 7 pages [14 pages with translation]. |
“Office Action”, Japan Patent Application No. 2020-543924, Nov. 24, 2021, 3 pages [6 pages with translation]. |
“Extended European Search Report”, European Patent Application No. EP19785057, Dec. 6, 2021, 8 pages. |
“Office Action”, Australia Patent Application No. 2020218172, Dec. 21, 2021, 4 pages. |
“Extended European Search Report”, European Patent Application No. 21187314.6, Dec. 10, 2021, 10 pages. |
Number | Date | Country | |
---|---|---|---|
20220022760 A1 | Jan 2022 | US |
Number | Date | Country | |
---|---|---|---|
63067757 | Aug 2020 | US | |
63055236 | Jul 2020 | US |